Abstract-PDCD5 (programmed cell death 5) is ubiquitously expressed in tissues, including the heart; however, the mechanism underlying the cardiac function of PDCD5 has not been understood. We investigated the mechanisms of PDCD5 in the pathogenesis of cardiac hypertrophy. Cardiac-specific PDCD5 knockout mice developed severe cardiac hypertrophy and impaired cardiac function, whereas PDCD5 protein was significantly increased in transverse aortic constriction mouse hearts and phenylephrine-stimulated cardiomyocytes. Overexpression of PDCD5 inhibited phenylephrine-induced cardiomyocyte hypertrophy, and knockdown of PDCD5 induced cardiomyocyte hypertrophy and aggravated phenylephrine-induced hypertrophy. The expression of PDCD5 protein was regulated by NFATc2 (nuclear factor of activated T cells c2) during hypertrophy. SERCA2a (sarco/endoplasmic reticulum Ca 2+ -ATPase 2a) expression was decreased in PDCD5-deficient mouse hearts because of increased ubiquitination. PDCD5-deficient cardiomyocytes displayed decreased calcium uptake rate, slowed decay of Ca 2+ transients, decreased calcium stores, and diastolic dysfunction. Moreover, reintroduction of PDCD5 in PDCD5-deficient mouse hearts reserved SERCA2a protein, suppressed NFATc2 protein, and rescued the hypertrophy and cardiac dysfunction. Our results revealed that PDCD5 is a novel target of NFATc2 in the hypertrophic heart and provides negative feedback to protect the heart against excessive hypertrophy via the stabilization of SERCA2a protein. 
C
ardiac hypertrophy is an adaptive response of the heart to diverse pathological stimuli, such as increased circulating humors or mechanical stresses, and is characterized by an increase in cell surface area and the reactivation of fetal cardiac genes.
1,2 Several signaling pathways have been implicated in the pathogenesis of cardiac hypertrophy, 3, 4 among which calcineurin/nuclear factor of activated T cells (NFAT) is a major signaling that has been extensively studied. 5 Calcineurin is activated in an intracellular calcium-dependent manner by hypertrophic stimuli, such as phenylephrine, Ang II (angiotensin II), or endothelin-1. 6 Activated calcineurin dephosphorylates NFAT, which translocates into the nucleus to activate hypertrophic transcription factors and hypertrophy-related genes, subsequently initiating hypertrophic processes. 7, 8 Compensatory hypertrophy allows the heart to preserve fundamental function and blood circulation; however, sustained hypertrophy is a risk factor of cardiac arrhythmia, heart failure, and sudden death. [9] [10] [11] Thus, the heart must develop an intrinsic defense mechanism to prevent cardiomyocyte hypertrophy. Indeed, endogenous antagonists targeting hypertrophic pathways have been identified. For example, cain, a calcineurin-binding protein, prevents agonist-induced cardiomyocyte hypertrophy by inhibiting calcineurin signals. 12, 13 Recently, another protein named carabin was reported as an endogenous inhibitor of calcineurin/NFAT, its carboxy-terminal domain interacts with calcineurin and inhibits cardiac hypertrophy, 14, 15 and IRF2BP2 (interferon regulatory factor 2-binding protein 2) was reported as a negative regulator in hypertrophy which directly interacts with the C-terminal transactivation domain of NFAT1. 16 More interestingly, MCIP1 (modulatory calcineurin interacting protein 1), which suppresses calcineurin activity by directly binding Moreover, MCIP1 deficiency exacerbates the hypertrophic response to activated calcineurin, 19 indicating that MCIP1 serves as negative feedback to prevent deleterious calcineurin activity. Undoubtedly, the exploration of additional endogenous hypertrophic suppressors has important implications for the development of therapeutic strategies against cardiac hypertrophy.
PDCD5 (programmed cell death 5) was initially identified as an apoptosis accelerator/enhancer 20, 21 and was later found to be involved in the pathogenesis of various diseases, such as human tumors, [22] [23] [24] autoimmune diseases, 25 inflammatory diseases, 26 cerebral ischemia/reperfusion injury, 27 and atherosclerosis. 28 In the heart, PDCD5 is upregulated in Ang II-or transverse aortic constriction (TAC)-induced hypertrophic cardiomyocytes 29 ; in addition, cardiac-specific overexpression of PDCD5 in mice leads to dilated cardiomyopathy and heart failure by increasing autophagic activity. 29 However, controversial data from systemic PDCD5-overexpressing mice showed that PDCD5 protects the heart from remodeling and preserves cardiac function in response to isoproterenol stimulation via the induction of autophagy and inhibition of apoptosis. 30 Considering these discordant results, it is of interest to clarify the function of PDCD5 in the regulation of cardiac hypertrophy using a loss-of-function approach with the PDCD5 knockout model. However, PDCD5-null mice are embryonic lethal around E13.5 because of placental defects, and the abnormal ventricular wall of the heart might be a consequence of the placental failure. 31 By generating a cardiac-specific PDCD5 knockout mouse model (αMHC [alpha myosin heavy chain]-Cre + /Pdcd5 fl/fl ), combined with the TAC-mediated hypertrophic mouse model, the present study investigated the role of PDCD5 in the heart, especially in the pathogenesis of cardiac hypertrophy. And unexpectedly, our study revealed a negative feedback of PDCD5 in the regulation of cardiac hypertrophy.
Materials and Methods
The authors declare that all supporting data are available within the article and its online-only Data Supplement.
Methods are available in the online-only Data Supplement.
Results

Cardiac-Specific Knockout of Pdcd5 Causes Hypertrophic Cardiomyopathy
PDCD5 is ubiquitously expressed in tissues, including the heart. To understand the function of PDCD5 in the heart, we generated a cardiac-specific Pdcd5 knockout mouse model using the Cre-loxP system to remove exon 2 to 3 of Pdcd5 (αMHC-Cre + /Pdcd5 fl/fl , PDCD5 CKO; Figure 1A ). The male PDCD5 CKO mice appeared weak and inactive compared with control littermates; up to 11.8% of male PDCD5 CKO mice died within 16 days after birth, and all PDCD5 CKO male mice died within 4 months ( Figure 1B) . Moreover, the survival rate of heterozygous knockout male mice (αMHC-Cre + /Pdcd5 fl/+ ) was also mildly decreased to 71.4% within 3 months after birth ( Figure 1B ). Echocardiography showed a thicker left ventricular posterior wall (LVPWd) and increased left ventricular mass/body weight ratio in heterozygous PDCD5 CKO hearts compared with control hearts (Pdcd5 fl/ fl and αMHC-Cre + mice; Figure 1C ). The LVPWd of homozygous PDCD5 CKO was not significantly altered; however, the left ventricular mass/body weight ratio was markedly increased, and the interventricular septal thickness at endsystole was also dramatically increased ( Figure 1C ; Table  S2 in the online-only Data Supplement). These data together with the thicker left ventricular wall thickness and unaltered internal dimension at end-diastole (Table S2) suggest that knockout of PDCD5 causes hypertrophic cardiomyopathy. Both homozygous and heterozygous PDCD5 CKO mice showed a significant decline in ejection fraction and percent fractional shortening compared with the control mice ( Figure 1C ; Table S2 ).
Histologically, homozygous and heterozygous PDCD5 CKO mice exhibited enlarged hearts and increased thickness of the left ventricular wall and interventricular septum compared with control mice at 8 weeks old ( Figure 1D ). Consistently, the ratio of heart weight to body weight of homozygous and heterozygous PDCD5 CKO mice was 1.6-and 1.3-fold greater than that of Pdcd5 fl/fl control mice, respectively, and the heart weight to tibia length ratio was 1.36-and 1.2-fold greater than that in Pdcd5 fl/fl control mice, respectively ( Figure 1D ). The cross-sectional area of cardiomyocytes from homozygous and heterozygous PDCD5 CKO mice increased to 195% and 154% of the cross-sectional area of cardiomyocytes from Pdcd5 fl/fl control mice, as shown by hematoxylin and eosin staining and wheat germ agglutinin staining ( Figure 1E ). Both mRNA and protein levels of ANP (atrial natriuretic peptide) were significantly increased in PDCD5 CKO mouse hearts ( Figure 1F ), further confirming that PDCD5 deficiency induces cardiac hypertrophy. Interestingly, although female PDCD5 CKO mice exhibited increased left ventricular mass to body weight ratios and increased ANP levels, their survival rate was similar to that of control mice ( Figure S1 ; Table S3 ). This discrepancy could possibly be associated with hormonal differences between male and female mice. Collectively, our data show that cardiac-specific knockout of PDCD5 causes cardiac hypertrophy.
To understand whether PDCD5 deficiency has clinical significance, we also performed preliminary experiments with blood samples from 4 hypertrophic cardiomyopathy patients who were clinically diagnosed based on echocardiographic results and medical history (Tables S4 and S5 ). Based on the structure of 3 regions of the PDCD5 protein, the ordered but not rigid N-terminal region (D3-R40), the core region (N41-Q101), and the C-terminal extension with a mobile and unstructured region (Q102-D118) and a dynamically frayed tail (S119-Y125), 32 we determined the gene sequence and found that there were more frame shift mutations in the N-terminal region and the core region. For example, a D3 insertion and a V109 deletion were found in hypertrophic cardiomyopathy patient blood samples (Table  S5 ), suggesting that a loss-of-function mutation in PDCD5 may contribute to the pathogenesis of hypertrophic cardiomyopathy patients. 
PDCD5 Is Upregulated During Cardiac Hypertrophy, and Reintroduction of PDCD5 Ameliorates PDCD5 Deficiency-Caused Cardiac Hypertrophy
To understand the possible role of PDCD5 in the pathogenesis of cardiac hypertrophy, we at first measured the changes of the expression level of PDCD5 in hypertrophic hearts compared with control hearts. In TAC-mediated pressure overload-induced hypertrophic mouse hearts, PDCD5 mRNA and protein levels significantly increased to 4.9-and 3.5-fold, respectively, compared with sham hearts (Figure 2A ). Consistently, in neonatal rat cardiomyocytes stimulated with phenylephrine (PE) for 48 hours, while ANP mRNA increased to 4.3-fold compared with untreated cardiomyocytes, PDCD5 mRNA and protein levels increased to 3.1-and 3-fold, respectively ( Figure 2B ). These data are consistent with previous findings that PDCD5 is upregulated in hypertrophic hearts and cardiomyocytes. 29 We then examined the response of cardiomyocytes to upregulated PDCD5. Surprisingly, we found that adenovirusmediated overexpression of PDCD5 (ad-PDCD5) had no effect on cardiomyocyte size and the level of ANP mRNA. However, PDCD5 overexpression dramatically attenuated the PE-induced increase in cardiomyocyte size and ANP mRNA level ( Figure 2C ), suggesting an inhibitory effect of PDCD5 on cardiomyocyte hypertrophy. In contrast, in cardiomyocytes transfected with ad-shPDCD5, we found that PDCD5 knockdown led to increased cardiomyocyte size and further aggravated the PE-induced increase in cell size ( Figure 2D ). Knockdown of PDCD5 also caused an increase in ANP mRNA level to 2.8-fold that of scrambled control cells; however, PDCD5 knockdown did not further increase the PE-induced upregulation of ANP mRNA ( Figure 2D ). Collectively, results from both gain-of-function and loss-offunction studies indicate that PDCD5 deficiency induces cardiomyocyte hypertrophy, whereas the high level of PDCD5 during cardiac hypertrophy may protect the heart against excessive hypertrophy.
To further confirm if cardiac hypertrophy-induced upregulation of PDCD5 provides negative feedback to protect the heart from excessive hypertrophy in vivo, we reintroduced PDCD5 through adenovirus-associated virus serotype 9 (AAV9) in PDCD5 CKO mouse hearts. Two weeks after intravenously injection, >70% of cardiomyocytes were infected with AAV9-ZsGreen-PDCD5 or AAV9-ZsGreen-lacZ adenovirus as visualized by green fluorescence signals, and ZsGreen-PDCD5 protein was expressed in PDCD5 CKO hearts ( Figure 2E ). PDCD5 CKO mice with or without PDCD5 re-expression were then subjected to TAC operation for 2 weeks. While TAC further increased LVPWd and decreased ejection fraction and fractional shortening in control PDCD5 CKO mouse hearts as compared with PDCD5 CKO sham mice, re-expression of PDCD5 by AAV9-ZsGreen-PDCD5 significantly suppressed TAC-induced increase of LVPWd and improved TAC-induced decrease of ejection fraction and fractional shortening ( Figure 2F ). Moreover, although re-expression of PDCD5 per se had no effect on LVPWd of PDCD5 CKO hearts, it significantly increased ejection fraction and fractional shortening of PDCD5 CKO hearts, as compared with AAV9-ZsGreen-lacZinfected control PDCD5 CKO mice ( Figure 2F ). Thus, the in vivo data support our notion that upregulated PDCD5 during cardiac hypertrophy negatively prevents the development of excessive hypertrophy.
NFATc2 Regulates PDCD5 Expression During Cardiac Hypertrophy
To investigate the underlying mechanism of PDCD5 upregulation during hypertrophy, we predicted a possible regulatory sequence in the PDCD5 promoter by in silico analysis. The sequence AGGAAA, a typical recognition site [5′-(A/T) GGAAA-3′] of NFAT 33, 34 was found in the PDCD5 promoter region. The NFATc2 transcription factor is an essential component of the calcineurin-dependent transcriptional pathway, a classic hypertrophic pathway. In HeLa cell lines transfected with luciferase reporter plasmids containing the PDCD5 promoter region (pGL3-PDCD5), cotransfection of the NFATc2 expression vector and pRL-TK increased PDCD5 promoter activity to 3.65-fold compared with cells cotransfected with the pCMV6-Entry vector, whereas NFATc2 expression had no effect on the luciferase activity in cells transfected with plasmids containing the mutant PDCD5 promoter ( Figure 3A) . The chromatin immunoprecipitation assay further showed that NFATc2 bound to the PDCD5 promoter by 150× compared with IgG control ( Figure 3B ). More importantly, in neonatal rat cardiomyocytes, transfection of myc-NFATc2 adenovirus increased the PDCD5 expression level to 2.1-fold compared with vector control cells ( Figure 3C ), supporting that PDCD5 is a target gene of NFATc2 and can be regulated by NFATc2 in cardiomyocytes.
Next, we explored the regulatory effect of NFATc2 on PDCD5 during PE-induced cardiomyocyte hypertrophy. In rat neonatal cardiomyocytes, while PE stimulation increased ANP mRNA expression, it also increased NFATc2 and PDCD5 mRNA expression ( Figure 3D ). Moreover, knockdown of NFATc2 abolished the PE-mediated upregulation of ANP, supporting the hypertrophic role of NFATc2 in cardiomyocytes. 35 In addition, knockdown of NFATc2 abolished PE-mediated PDCD5 upregulation, which was consistent with the regulatory effect of NFATc2 on PDCD5 ( Figure 3D ), supporting that PDCD5 is a downstream factor of NFATc2 during cardiomyocyte hypertrophy.
In heterozygous and homozygous PDCD5 CKO mouse hearts, we also found that NFATc2 protein levels were significantly increased compared with Pdcd5 fl/fl and αMHC-Cre + control mouse hearts ( Figure 3E ). Moreover, reintroduction of PDCD5 in PDCD5 CKO mouse hearts largely suppressed NFATc2 protein level in both control PDCD5 CKO mice and PDCD5 CKO mice subjected to TAC ( Figure 3F ), suggesting that PDCD5 may directly or indirectly negatively regulate NFATc2 expression. Together, these data suggest that PDCD5 is a novel endogenous target of NFATc2 in hypertrophic hearts that provides negative feedback to protect the heart from excessive hypertrophy.
PDCD5 Regulates Sarcoplasmic Reticulum Calcium Content in Hypertrophic Cardiomyocytes
In the heart, calcium is a center player in regulating physiological and pathological functions. To understand the possible involvement of calcium signals in PDCD5-mediated cardiac hypertrophy, we measured calcium content in response to caffeine stimulation, as indicated by the normalized Fluo-4 AM fluorescence index F/F 0 (F 0 refers to the level before caffeine stimulation), in rat neonatal cardiomyocytes. We found that PE stimulation decreased sarcoplasmic reticulum (SR) Ca 2+ release in response to caffeine stimulation ( Figure 4A and 4B) , which was in general agreement with the decreased SR Ca 2+ content in hypertrophic hearts. 36 Although overexpression of PDCD5 increased SR Ca 2+ release in response to caffeine stimulation, it also significantly reversed the PE-induced reduction of SR Ca 2+ release ( Figure 4A-4C) , suggesting that the protective effect of PDCD5 on hypertrophic cardiomyocytes might be achieved by increasing SR calcium content. Consistently, knockdown of PDCD5 in cardiomyocytes caused a 7.9% decrease in the peak amplitude of calcium concentration in response to caffeine stimulation and further reduced the PE-induced decrease of SR calcium content ( Figure 4C  and 4D) . Collectively, our results suggest that changes in 
PDCD5-regulated SR Ca
2+ content may contribute to the progression of cardiomyocyte hypertrophy.
PDCD5 Interacts and Stabilizes SERCA2a (Sarco/ Endoplasmic Reticulum Ca
2+ -ATPase 2a) Protein in Mouse Hearts
Next, we analyzed protein expression profiles in homozygous PDCD5 CKO and Pdcd5 fl/fl mouse hearts with NanoLC-MS/MS, and we found altered expression levels of multiple hypertrophy-related proteins in PDCD5 CKO mouse hearts. Among the altered proteins, the most dramatically decreased protein is SERCA2a ( Figure 5A ). Western blot results confirmed that SERCA2a protein in PDCD5 CKO mouse hearts decreased to ≈30% of that in control hearts ( Figure 5B ), which is in general agreement with previous studies that showed decreased SERCA2a expression in hypertrophic cardiomyopathy patients [37] [38] [39] and animal models. 40 , 41 Interestingly, we found that PDCD5 interacted with SERCA2a in mouse hearts ( Figure 5C ). Furthermore, overexpression of PDCD5 in rat neonatal cardiomyocytes reduced the amount of polyubiquitinated SERCA2a, whereas knockdown of PDCD5 increased the SERCA2a ubiquitination ( Figure 5C) affinity of SERCA2a does not change in PDCD5 CKO mouse hearts ( Figure 5D ). Also, we measured SERCA2a protein level in PDCD5 CKO mice reintroduced with PDCD5 subjected to TAC or not. Western blot showed that re-expression of PDCD5 significantly reserved SERCA2a protein level in PDCD5 CKO mouse hearts and even in hearts of re-expression of PDCD5 subjected to TAC ( Figure 5E ). Together, our data suggest that 
PDCD5 Deficiency Causes Depressed Contractile Activity, and Overexpressing SERCA2a Ameliorates PDCD5 Knockdown-Induced Cardiomyocyte Hypertrophy
To further understand the effect of decreased SERCA2a on SR calcium regulation and cardiomyocyte contraction in PDCD5 deficiency hearts, we measured Ca 2+ transients in single adult cardiomyocytes isolated from PDCD5 CKO and Pdcd5 fl/fl control mouse hearts by electronically pacing cells with 10 V at 0.5 Hz. Fluorescent intensity of the ratiometric Ca 2+ probe Fura-2 showed that the Tau of Ca 2+ decay in control cardiomyocytes was 0.247 seconds and increased to 0.328 seconds in PDCD5-deficient cardiomyocytes ( Figure 6A) , further suggesting the slowdown of calcium uptake. Moreover, the sarcomere contraction amplitude of PDCD5-deficient cardiomyocytes in response to electronic pacing decreased to 0.82-fold of the sarcomere contraction amplitude of control cardiomyocytes ( Figure 6A ). We also measured calcium content in response to caffeine stimulation and found that the Fluo-4 AM fluorescence index F/F 0 decreased from 3.201±0.17 in control cardiomyocytes to 2.292±0.11 in PDCD5-deficient cardiomyocytes ( Figure 6B ).
Decreased SR calcium content and prolonged calcium transients are hallmarks of cardiomyocyte failure during hypertrophy, possibly because of insufficient calcium reuptake into the SR or reduced SERCA expression and activity. 42, 43 Therefore, we evaluated left ventricular diastolic function through transmitral flow and tissue Doppler echocardiography ( Figure 6C ). PDCD5 CKO mice displayed specific patterns of impaired left ventricular relaxation compared with control mice: the peak E velocity was significantly decreased, resulting in the decreased early to late diastolic transmitral flow velocity (E/A) ratio and the increased 2+ in response to 10 μmol/L caffeine stimulation in cardiomyocytes transfected with ad-SERCA2a with or without ad-shPDCD5 cotransfection for 48 h; n=60 cells in each group from 5 independent experiments. Scale bar, 25 μm. Quantifications of peak amplitude (right); ***P<0.001 vs the ad-lacZ group; and ##P<0.01 vs the sh-PDCD5 group. E, Surface areas (left) and ANP (atrial natriuretic peptide) mRNA levels (right) of cardiomyocytes transfected with ad-SERCA2a with or without ad-shPDCD5 cotransfection; n=50 random cells in each group from 3 independent experiments and n=3 independent experiments. ***P<0.001 vs the ad-lacZ group; and #P<0.05 vs the sh-PDCD5 group. F, Schematic view of PDCD5 regulating cardiac hypertrophy via a negative feedback mechanism in the heart. October 2018 E to early diastolic mitral annular tissue velocity (E/e′) ratio ( Figure 6C) .
Next, we overexpressed SERCA2a by Ad-SERCA2a in PDCD5 knockdown cardiomyocytes. We found that overexpressing SERCA2a increased the PDCD5-deficiencyinduced decrease of SR calcium content ( Figure 6D ). More importantly, SERCA2a overexpression reversed the PDCD5-deficiency-caused increase of cell area and ANP level ( Figure 6E) . Thus, these data showed that PDCD5 deficiency reduces the SR calcium content and inhibits cardiac contractile activity because of the decreased SERCA2a expression and subsequent calcium uptake into the SR and that SERCA2a is necessary in the effect of PDCD5 deficiency-caused cardiac hypertrophy. Together, our in vivo and in vitro data support our notion that upregulated PDCD5 during cardiac hypertrophy negatively prevents the development of excessive hypertrophy ( Figure 6F ).
Discussion
In the present study, we found that PDCD5 deficiency in the mouse heart led to severe hypertrophic cardiomyopathy and cardiac dysfunction. Consistently, knockdown of PDCD5 induced cardiomyocyte hypertrophy and enhanced hypertrophy after PE stimulation. Moreover, PDCD5 is upregulated in pressure overload-induced hypertrophic mouse hearts and PE-stimulated hypertrophic cardiomyocytes. Although PDCD5 highly expresses in heart tissue, 20 studies on its cardiac functions are scarce, and the results are controversial. In Ang II-or TAC-induced hypertrophic mouse hearts, PDCD5 expression was upregulated. 29, 30 Although highly overexpressing PDCD5 in the heart caused dilated cardiomyopathy and heart failure, mice with moderate overexpression of PDCD5 had normal basal cardiac function but were susceptible to Ang II-induced hypertrophy. 29 In contrast, a study on isoproterenolinduced hypertrophic mouse hearts showed that PDCD5 was downregulated and that systemic overexpression of PDCD5 protected the heart from isoproterenol-induced hypertrophy and preserved cardiac function. 30 Different protein expression levels, experimental mouse models, and hypertrophic stimuli might underlie the discrepancy between these findings. One speculation is that a moderate level of cardiac PDCD5 overexpression prevents hypertrophic progression in TAC mice while highly overexpressed PDCD5 causes cardiomyocyte death and subsequently dilated cardiomyopathy and heart failure. Different hypertrophic stimuli may contribute to the controversial results of PDCD5 protein level during cardiac hypertrophy, that is, upregulated in Ang II-and TAC-induced hypertrophy while downregulated in isoproterenol-induced one. Indeed, PE and Ang II, but not isoproterenol, mediate cardiac hypertrophy through calcineurin/NFAT pathway, in consistent with our findings. Importantly, our preliminary data with samples from clinical patients show more mutations in PDCD5 gene from hypertrophic cardiomyopathy patients, suggesting a clinical significance of PDCD5 deficiency; however, additional studies with more clinical samples and careful interpretation are required to elucidate the fundamental role of PDCD5 in the pathogenesis of cardiac diseases.
In PDCD5-deficient hearts and cardiomyocytes, we found dramatically decreased SERCA2a protein levels. Moreover, the reintroduction of PDCD5 in PDCD5-deficient mouse hearts significantly reserved SERCA2a protein level, both at basal level and in response to TAC operation, suggesting a regulatory effect of PDCD5 on SERCA2a protein. Posttranslational modifications, such as SUMOylation (small ubiquitin-related modifier) or acetylation, have been reported to alter SERCA2a stability and activity in failure hearts. 44 Previous studies found that PDCD5 could stabilize p53 protein and histone acetyltransferase Tip60. 45, 46 In U2OS cells, PDCD5 interacted with p53 and blocked ubiquitin ligase Mdm2-mediated degradation of p53. 45 The present study found that PDCD5 interacted with SERCA2a and stabilized SERCA2a by inhibiting its ubiquitination; however, whether PDCD5 interacts with SUMO or acetyltransferases or other ubiquitin ligases to mediate SERCA2a stability needs further study. Consistent with the decreased SERCA2a protein in PDCD5-deficient hearts, we also found reduced Ca 2+ uptake rate and SR calcium content, slowed decay of calcium transients, and inhibited contractile and diastolic activity. Calcium is a central player in the regulation of cardiomyocyte excitation-contraction coupling, and disruption of calcium homeostasis is an important mechanism underlying heart diseases, including hypertrophy and heart failure. 47, 48 In particular, downregulation of SERCA and SR calcium transport has been reported in animal models of both pressure overload-induced hypertrophy and genetic hypertrophic cardiomyopathy, as well as in hypertrophic cardiomyopathy patients. 36, 37, [39] [40] [41] More recently, studies using induced pluripotent stem cells from hypertrophic cardiomyopathy patients with single mutations in the MYH7 gene also reported decreased expression of SERCA2a and reduced calciuminduced calcium release from the SR. 49 Studies on cardiacspecific SERCA2a deletion mouse models report, in general, impaired cardiac contractility and relaxation 50 ; conversely, the overexpression of SERCA or activation of SERCA activity restores cardiac function. 51, 52 In concordance with these previous studies, our current study provides an independent line of evidence showing that there are aberrations in SERCA2a expression and calcium handling in PDCD5 deficiency-mediated cardiac hypertrophy. More importantly, reintroduction of PDCD5 not only improved PDCD5 deficiency-caused cardiac hypertrophy but also largely reserved SERCA2a protein, no matter with or without TAC challenge. The effect of PDCD5 on cardiac hypertrophy may therefore be, at least partially, attributed to the regulation of calcium handling processes through SERCA2a. Intriguingly, the protein expression profiles by NanoLC-MS/MS also showed a significant increase of Na + -Ca 2+ exchanger 1 (NCX1) in PDCD5 CKO mouse hearts. NCX1 primarily mediates Ca 2+ extrusion during cardiac relaxation to compete with SERCA in cardiomyocytes. An increase of NCX1 and a decrease of SERCA have been found in cardiac hypertrophy and heart failure. 39, 43, 53 Indeed, the upregulated NCX1 could directly decrease SR loading, thus contributes concomitantly with the decreased SERCA to cardiac dysfunction. 54, 55 The present study find that PDCD5 deficiency causes decreased SERCA2a and reduced SR Ca 2+ uptake rate and content; however, it could not exclude the possible contribution of the increased NCX1 on PDCD5-deficiency-induced cardiac hypertrophy.
Our finding that PDCD5 is upregulated in TAC-mediated hypertrophic mouse hearts and PE-stimulated hypertrophic cardiomyocytes whereas overexpression of PDCD5 attenuates PE-induced cardiomyocyte hypertrophy suggests that PDCD5 is a negative feedback molecule for cardiac hypertrophy. The in vivo results that reintroduction of PDCD5 in αMHC-Cre
fl/fl mouse hearts improved the hypertrophy and cardiac dysfunction at basal level and after TAC operation further support the negative feedback effect of PDCD5 on cardiac hypertrophy. A mechanism underlying the upregulation of PDCD5 during hypertrophy was identified by the observation that NFATc2 directly regulates PDCD5 expression. Previous studies have demonstrated that NFAT transcription factors are critical for the calcineurin-dependent transcriptional pathway in cardiac hypertrophy. 5, 8, 56 Consistent with our finding, upregulation of PDCD5 was also observed in Ang II-but not isoproterenol-induced hypertrophic hearts, 29, 30 supporting the regulatory effect of NFATc2 on PDCD5 during cardiac hypertrophy, as PE and Ang II could activate calcineurin/NFAT activity while isoproterenol could not. Four calcineurin-sensitive NFATc isoforms, NFATc1, NFATc2, NFATc3, and NFATc4, are expressed in ventricular cardiomyocytes. 35, 56 Among them, NFATc2 is the most abundant isoform and plays a major role in pathological cardiac remodeling and heart failure. 56 Whether other NFAT isoforms are involved in the NFAT-PDCD5 negative feedback mechanism during hypertrophy requires additional study. Interestingly, we noticed that NFATc2 protein levels are increased in PDCD5-deficient mouse hearts. A plausible reason is that abnormal calcium signaling in the PDCD5 deficiency-mediated hypertrophic mouse heart, that is, elevated intracellular calcium concentrations because of decreased SR calcium uptake, leads to the upregulation of NFATc2. Indeed, in many cell types including cardiomyocytes, changes in intracellular calcium concentrations can affect gene expression via the Ca 2+ /calmodulin-dependent activation of the calcineurin-NFAT pathway. The increased cytoplasmic Ca 2+ activates calcineurin that dephosphorylates NFAT, 8 the dephosphorylated NFAT then translocates into the nucleus to activate hypertrophic transcription factors and hypertrophy-related genes. 7, 8 For example, increased nuclear NFAT levels or NFAT activity has been observed in induced pluripotent stem cell-derived cardiomyocytes from MYH7 gene mutation-induced hypertrophic cardiomyopathy patients exhibiting decreased SERCA2a expression and reduced SR calcium release. 49 Consistent with studies, PDCD5 re-expression, in PDCD5-deficient mouse hearts with or without challenged by TAC operation, caused reserved SERCA2a protein as well as suppressed NFATc2 protein level. These findings further suggest that PDCD5 not only is a target gene of NFATc2 to negatively regulate cardiac hypertrophy but also negatively regulates NFATc2 per se, possibly because of SERCA2a-mediated calcium signaling.
In conclusion, the present study outlines a novel pathway involving PDCD5 in the pathogenesis of cardiac hypertrophy ( Figure 6F ). Although PDCD5 deficiency induces hypertrophic cardiomyopathy via decreased SERCA2a expression and reduced SR calcium uptake rate and content, PDCD5 expression is upregulated in response to hypertrophic stimuli through NFATc2 activation, which in turn provides a negative feedback on NFATc2-mediated cardiac hypertrophy.
Perspectives
Endogenous regulatory mechanisms are required to prevent excessive cardiac hypertrophy. Here, we found that pressure overload-induced cardiac hypertrophy causes increased PDCD5 protein level, and increasing PDCD5 attenuates overload-induced cardiac hypertrophy and improves cardiac function. Cardiac-specific knockout of PDCD5 leads to severe cardiac hypertrophy. Moreover, PDCD5 is a target of the NFATc2 during hypertrophy, and the upregulated PDCD5 negatively regulates cardiac hypertrophy by increasing SR calcium content through stabilizing SERCA2a protein. Thus, we identify PDCD5 as an intrinsic negative regulator of cardiac hypertrophy and provide a potential therapeutic target for preventing excessive cardiac hypertrophy. 
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